{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:28:38Z","timestamp":1772166518273,"version":"3.50.1"},"reference-count":16,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The patterns of dupilumab use, the first systemic drug approved for the treatment of atopic dermatitis (AD), is not well understood in the context of off\u2010label systemic medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To describe patterns of prescribing, switching and discontinuing systemic AD drugs, before and after the approval of dupilumab and understand variables associated with dupilumab prescription.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using longitudinal claims data, we identified patients with AD who initiated a systemic therapy (dupilumab, cyclosporine, methotrexate, azathioprine, mycophenolate) from March 2015 to February 2021, with a washout period of 1\u2009year. We used Sankey plots to visualize longitudinal patterns of use at 3, 6, and 12\u2009months and logistic regression to determine associates of dupilumab prescription.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The number of patients starting systemic treatment increased from 319 before dupilumab approval to 1358 after. Dupilumab use increased from 72% to 84%. In 2019\u20132020, 36% of patients discontinued systemic treatment within a year compared to 62% in 2015\u20132016. 92% of patients who started dupilumab in 2020\u20132021 had received no other systemic treatment before. Patients &lt;60\u2009years and those who used steroid\u2010sparing topical treatments were more likely to receive dupilumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Among new users of a systemic treatment for AD, dupilumab was most used treatment by far.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5586","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T15:04:00Z","timestamp":1671289440000},"page":"567-576","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Use patterns of systemic immunomodulators in the United States before and after dupilumab approval in adults with atopic dermatitis"],"prefix":"10.1002","volume":"32","author":[{"given":"Priyanka","family":"Anand","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology, Department of Medicine Brigham and Women's Hospital  Boston Massachusetts USA"},{"name":"Harvard Medical School  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2575-467X","authenticated-orcid":false,"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology, Department of Medicine Brigham and Women's Hospital  Boston Massachusetts USA"},{"name":"Harvard Medical School  Boston Massachusetts USA"},{"name":"Harvard T. H. Chan School of Public Health  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[{"name":"Harvard Medical School  Boston Massachusetts USA"},{"name":"Department of Dermatology Brigham and Women's Hospital  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4304-5271","authenticated-orcid":false,"given":"Maria C.","family":"Schneeweiss","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology, Department of Medicine Brigham and Women's Hospital  Boston Massachusetts USA"},{"name":"Harvard Medical School  Boston Massachusetts USA"},{"name":"Department of Dermatology Brigham and Women's Hospital  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2010.06.003"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.08.028"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.030"},{"issue":"10","key":"e_1_2_10_5_1","first-page":"590","article-title":"Atopic dermatitis: diagnosis and treatment","volume":"101","author":"Frazier W","year":"2020","journal-title":"Am Fam Physician"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2012.09.002"},{"key":"e_1_2_10_7_1","unstructured":"U.S. Food & Drug Administration.FDA approves new eczema drug Dupixent. U.S. Food & Drug Administration 2017. Accessed October 18 2022.https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-eczema-drug-dupixent"},{"key":"e_1_2_10_8_1","article-title":"Dupixent approved for treating eczema patients aged 12 to 17","author":"The National Eczema Association","year":"2019","journal-title":"The National Eczema Association"},{"key":"e_1_2_10_9_1","article-title":"FDA approves Duilumab for atopic dermatitis in children","author":"Barrett J","year":"2020","journal-title":"Drug Topics"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.12.022"},{"issue":"9","key":"e_1_2_10_11_1","first-page":"532","article-title":"Dupilumab (Dupixent): an Interleukin\u20104 receptor antagonist for atopic dermatitis","volume":"43","author":"D'Ippolito D","year":"2018","journal-title":"P t"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14371"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/jd9.0000000000000143"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3336"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/m18\u20103079"},{"key":"e_1_2_10_16_1","article-title":"FDA widens use of dupilumab to children with AD as young as 6 months","author":"AJMC Staff","year":"2022","journal-title":"Am J Manag Care"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5586","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.5586","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5586","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T13:23:23Z","timestamp":1692710603000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1002\/pds.5586"],"URL":"https:\/\/doi.org\/10.1002\/pds.5586","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,28]]},"assertion":[{"value":"2022-08-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}